#871: The “Divine Leaf” with 8,000+ Years of Use — Exploring the Many Benefits of Coca with Dr. Andrew Weil and Wade Davis

What It Covers

Tim Ferriss hosts ethnobotanist Wade Davis and integrative medicine pioneer Dr. Andrew Weil for an 82-minute examination of coca leaf — a plant with 8,000 years of documented human use across Andean and Amazonian cultures. They cover its medicinal properties, cultural significance, the racist policy history that criminalized it, and concrete steps toward scientific rehabilitation and commercial legalization.

Key Questions Answered

• •Whole-plant pharmacology: Coca leaf contains 14 alkaloids, of which cocaine is just one. The remaining 13 have never been studied. The full alkaloid complex produces paradoxical effects — simultaneously treating both diarrhea and constipation — suggesting the body selects which receptors to activate based on need. Isolated cocaine cannot replicate this. Researchers and entrepreneurs should target whole-leaf formulations, not extracts.
• •Metabolic and blood sugar regulation: A documented study showed Andean subjects riding exercise bikes normalized blood glucose at any point they began chewing coca after a carbohydrate load. Andean populations with genetic predisposition to type 2 diabetes show near-zero incidence when maintaining traditional coca use and diet. Dr. Christopher McCurdy at the University of Florida is currently initiating animal studies on this mechanism.
• •Stimulant profile vs. coffee and pharmaceuticals: Coca leaf produces focus and sustained energy without the subjective sensation of stimulation, no post-use crash, and no physical dependency upon cessation — contrasting sharply with caffeine, modafinil, and amphetamines. Wade Davis attributes authoring 24 books and producing 50 films partly to daily coca use. The effect is described as removing low-level existential noise rather than adding stimulation.
• •Policy leverage points: Coca sits in Schedule II of the U.S. Controlled Substances Act — not Schedule I like cannabis and psychedelics — because cocaine has recognized pharmaceutical uses in ophthalmology and dentistry. This scheduling makes research significantly cheaper and faster to initiate. A single FDA-approved therapeutic indication, such as GI disorders or carbohydrate metabolism regulation, could begin unlocking commercial pathways for coca-based products.
• •Research funding entry point: Early psilocybin depression studies at Johns Hopkins were funded for approximately $50,000 per study. Dr. Christopher McCurdy (University of Florida, mcCurdy spelled M-c-C-u-r-d-y) recently secured a legal coca leaf supply after extensive regulatory delays and is beginning whole-leaf alkaloid research. The Beneficial Plant Research Association (bpra.org) coordinates funding and scientific efforts specifically targeting coca's therapeutic applications.
• •Decoupling licit coca from cocaine production: Legalizing coca leaf export would not meaningfully disrupt cocaine cartel operations, which already function outside legal frameworks at massive scale. However, it would create taxable revenue for Colombia, provide 250,000 farming families a legal market, reduce deforestation pressure by eliminating the need to push cultivation into remote rainforest areas, and allow existing cleared land to be used productively for legitimate leaf production.